Research

On this page you will find ongoing clinical studies within the Gentle Radiotherapy consortia. Should you know of a study that isn’t listed here? Please let us know at contact@gentleradiotherapy.se

PARAPLY

Patients receiving radiotherapy for Prostate Cancer with high risk of Lymph node metastasis 

Principal Investigator: Camilla Thellenberg Karlsson (Umeå University)

Contact: camilla.thellenberg@onkologi.umu.se

Participating sites: Umeå

Estimated patient enrollment: 85

Start date: 2014

 

Summary

PARAPLY is an intervention study where the proposed dominant lesion in the prostate is boosted to 84 Gy. The study includes an exploratory part searching for image-based biomarkers for prostate cancer.

Assigned interventions (summarize MRI techniques and treatment protocol):
Serial investigations with Acetate C11 PET-MRI before start, during combined therapy for high-risk prostate cancer and in the follow-up period for the imaging biomarker part. Intervention is made with simultaneous integrated boost to the dominant lesion in the prostate defined by a combination of PET and MRI data.


 MORRIS

– Multimodal Monitoring of Radiotherapy Response in Squamous cell cancer

Principal Investigator: Björn Zackrisson (Umeå University)

Contact: Bjorn.Zackrisson@umu.se

Participating sites: Umeå and Lund

Estimated patient enrollment: 412

Start date: May 2015

Summary

The study’s aim is to define imaging and molecular bio-markers for prediction of radiotherapy response of squamous cell carcinomas, in an early treatment phase.
Assigned interventions (summarize MRI techniques and treatment protocol):
Patients with squamous cell carcinoma of the head & neck, anal canal, cervix, esophagus or lung will be assessed before start of radiotherapy and 1-2 weeks after start. Multi-parametric MRI and 18F-FDG PET will be performed in parallel to metabolomic analyses of tumour tissue. The investigators will correlate changes in imaging bio-markers to corresponding changes in tissue or blood bio-markers by repeated imaging and biopsies for better understanding of the image parameters.
The data from the two assessments will be used for identifying imaging bio-markers, predictive for outcome. The patient data will be divided into one set of data for hypothesis generation and another set for validation


 

MOVE

Principal Investigator: Camilla Thellenberg Karlsson (Umeå University)

Contact: camilla.thellenberg@onkologi.umu.se

Participating sites: Umeå

Estimated patient enrollment: 10

Start date: 2014

Summary

Exploratory study looking at movement of prostate, vesicles and lymphnodes during RT fractions and between RT fractions

Assigned interventions (summarize MRI techniques and treatment protocol):
5 examinations during radiotherapy
Examinations performed on 1.5 T scanner for first 5 patients and will be performed on 3T PET/MR scanner for the last 5 patients.
High resolution T2W sequence to identify lympnodes and a 10 min Cine sequence to look movement during typical RT fraction.


GOLD ATLAS

Contact: Tufve Nyholm (tufve.nyholm@radfys.umu.se), Adalsteinn Gunnlaugsson, (adalsteinn.gunnlaugsson@skane.se), Karin Söderström (karin.soderstrom@onkologi.umu.se)

Participating sites: Umeå University Hospital, Skåne University Hospital, Sahlgrenska University Hospital, Karolinska University Hospital

Participating Industrial partners: Raysearch, Spectronics

Estimated patient enrollment: 60
Start date: Q1 2015

Summary
The aim of this project is to develop an MRI-based reference atlas of organs at risk (OARs) in the head and neck and pelvic regions. A multi-center approach will be applied where radiation oncologists and radiologists from the participating centers will join to define the most important OARs. Patients with limited tumor burden in the head and neck and pelvic regions will be included and scanned with predefined MRI sequences in the treatment position. Target delineation will be done according to consensus guidelines using the Raystation treatment system.

 

MRI-PLANNER 

– MRI Only Treatment Planning in the clinical setting

Principal Investigator: Carl Siversson

Contact: Carl Siversson (carl.siversson@spectronic.se)

Participating sites: Umeå University Hospital, Skåne University Hospital, Sahlgrenska University Hospital

Participating Industrial partners: Spectronic Medical AB (Helsingborg, Sweden)

Estimated patient enrollment: 170
Start date: Q4 2015

MriPlanner (Spectronic Medical AB, Helsingborg, Sweden) is a commercial solution to enable an MRI only workflow in routine radiotherapy planning. MriPlanner utilizes MRI and advanced image processing algorithms to generate synthetic CT images that can replace conventional CT for dosimetric calculations. In a recently published pilot study [1], the method has showed very promising initial clinical results.

In the study to be performed here the performance of MriPlanner will be verified with a large set of prostate cancer images acquired at multiple clinical sites. In particular, the study aims at verifying the method’s robustness to variations in patient anatomy and also to variations in image acquisition procedures. Following this study MriPlanner will be introduced on the international market as the first independent solution to enable an MRI only radiotherapy planning workflow in clinical routine.